Bio-Techne has agreed to purchase Cliniqa, which manufactures and markets quality controls, calibrators and bulk reagents used in the clinical diagnostic market.
The addition of Cliniqa adds important capabilities to Bio-Techne as we continue to solidify our market presence and expand our business into key adjacent markets, such as immunodiagnostics,” said Charles Kummeth, President and CEO, Bio-Techne.
“We believe this deal provides an excellent path forward for our customers and employees while also providing significant value for the shareholders,” said Kevin Gould, CEO, Cliniqa
Terms of the deal have not been disclosed.
Cliniqa’s controls and reagents are used in different diagnostic tests for pathologies, including cardiac disease, diabetes, cancer, immunological disorders, therapeutic drug monitoring, urine analysis and toxicology.
According to Bio-Techne, Cliniqa received 510(k) approval for around 165 products from the US Food and Drug Administration.